Immunomodulation by Interleukin-10 Therapy Decreases the Incidence of Relapse and Prolongs the Relapse-free Interval in Psoriasis
- 1 April 2002
- journal article
- clinical trial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 118 (4), 672-677
- https://doi.org/10.1046/j.1523-1747.2002.01731.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Interleukin-10 Promoter Polymorphism in PsoriasisJournal of Investigative Dermatology, 2001
- Effects of Systemic Interleukin-10 Therapy on Psoriatic Skin Lesions: Histologic, Immunohistologic, and Molecular Biology FindingsJournal of Investigative Dermatology, 2001
- Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte MaturationJournal of Investigative Dermatology, 2001
- Treatment of Psoriasis with Interleukin-10Journal of Investigative Dermatology, 1998
- IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.Journal of Clinical Investigation, 1998
- Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study GroupGastroenterology, 1997
- Interleukin‐10 inhibits IgE‐mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytesEuropean Journal of Immunology, 1995
- The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated ResponseJournal of Investigative Dermatology, 1993
- Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytesImmunology Today, 1986
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978